Home > Riviste > International Angiology > Fascicoli precedenti > International Angiology 2017 October;36(5) > International Angiology 2017 October;36(5):496-7

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Publication history
Estratti
Per citare questo articolo

INTERNATIONAL ANGIOLOGY

Rivista di Angiologia


Official Journal of the International Union of Angiology, the International Union of Phlebology and the Central European Vascular Forum
Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,37


eTOC

 

LETTERS TO THE EDITOR  


International Angiology 2017 October;36(5):496-7

DOI: 10.23736/S0392-9590.17.03819-6

Copyright © 2017 EDIZIONI MINERVA MEDICA

lingua: Inglese

Extended use of sulodexide, apixaban, rivaroxaban and dabigatran in venous thromboembolism: indirect comparison of clinical trials

Witold TOMKOWSKI 1, Paweł KUCA 1 , Angelo A. BIGNAMINI 2, Giseppe M. ANDREOZZI 3

1 Polish Foundation against Thrombosis, National Tuberculosis and Lung Diseases Research Institute, Cardio-Pulmonary Intensive Care, Warsaw, Poland; 2 School of Specialization in Hospital Pharmacy, Department of Pharmaceutical Sciences, University of Milan, Milan, Italy; 3 Unit of Angiology, University Hospital, Padua, Italy


PDF  


inizio pagina

Publication History

Article first published online: June 21, 2017
Manuscript accepted: June 5, 2017
Manuscript revised: May 24, 2017
Manuscript received: January 25, 2017

Per citare questo articolo

Tomkowski W, Kuca P, Bignamini AA, Andreozzi GM. Extended use of sulodexide, apixaban, rivaroxaban and dabigatran in venous thromboembolism: indirect comparison of clinical trials. Int Angiol 2017;36:496-7. DOI: 10.23736/S0392-9590.17.03819-6

Corresponding author e-mail

p.kuca@igichp.edu.pl